On June 26, 2025, HC Wainwright & Co. analyst Raghuram Selvaraju reiterated a "Buy" rating on Cognition Therapeutics (CGTX, Financial), maintaining the price target at USD 3.00. This decision reflects confidence in CGTX, consistent with the previous rating and price target.
The current price target of USD 3.00 remains unchanged since the prior assessment, indicating no significant change in projected value according to the analyst's evaluation. The "Buy" recommendation suggests a positive outlook for Cognition Therapeutics (CGTX, Financial), aligning with the ongoing assessment of the company's growth potential.
Cognition Therapeutics (CGTX, Financial) is listed on the NASDAQ exchange, and the maintained target price and rating by HC Wainwright & Co. highlight the analyst's steady confidence in the company's performance and prospects.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 5 analysts, the average target price for Cognition Therapeutics Inc (CGTX, Financial) is $5.40 with a high estimate of $8.00 and a low estimate of $2.00. The average target implies an upside of 1,700.00% from the current price of $0.30. More detailed estimate data can be found on the Cognition Therapeutics Inc (CGTX) Forecast page.
Based on the consensus recommendation from 5 brokerage firms, Cognition Therapeutics Inc's (CGTX, Financial) average brokerage recommendation is currently 1.8, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
